Navigation Links
RotaTeq Gets US Approval

A vaccine called RotaTeq for rotavirus has been approved by the US. The rotavirus which gives rise to vomiting and diarrhea claims the lives of about 500,000 children across the world annually. // In one of the largest clinical trials in history, Merck, the medicine's maker tested the vaccine on more than 70,000 children that showed it was safe and remarkably effective.

Rotavirus is a highly contagious virus that causes severe dehydrating diarrhea in infants and young children. While such deaths in the US are rare, the disease is one of the world's deadliest childhood illnesses, said Umesh Parashar, a medical officer at the respiratory and enteric viruses' branch of the Center for Disease Control and Prevention.

A set of three oral doses will cost $187.50, making it one of the most expensive vaccines. Marie-Paule Kieny, director of the initiative for vaccine research at the Marie-Paule Kieny, said they were committed to make RotaTeq available at a discount price in the developing countries.

Edited (IANS)
'"/>




Page: 1

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. Better Communication With FDA Could Speed Up Approval Of New Drugs
6. Nerve Stimulator for Depression Though Not Effective Was Given Approval
7. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
8. Global Education Net Pvt Medical College Gets MCI Approval
9. Approval of Drugs for the Treatment of Late-Stage Cancer
10. Lupin Gets USFDA Approval For Quinapril Tablets
11. Ciplas HIV Drug Gets FDA Approval
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: RotaTeq Gets Approval

Breaking Medicine Technology:Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 1Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 2Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 3Clarient Reports Second Quarter Revenue Up 40 Percent 53673 1Clarient Reports Second Quarter Revenue Up 40 Percent 53673 2Clarient Reports Second Quarter Revenue Up 40 Percent 53673 3Clarient Reports Second Quarter Revenue Up 40 Percent 53673 4Clarient Reports Second Quarter Revenue Up 40 Percent 53673 5Clarient Reports Second Quarter Revenue Up 40 Percent 53673 6Clarient Reports Second Quarter Revenue Up 40 Percent 53673 7Clarient Reports Second Quarter Revenue Up 40 Percent 53673 8Clarient Reports Second Quarter Revenue Up 40 Percent 53673 9Clarient Reports Second Quarter Revenue Up 40 Percent 53673 10Cambrex Reports Second Quarter 2009 Results 53671 1Cambrex Reports Second Quarter 2009 Results 53671 2Cambrex Reports Second Quarter 2009 Results 53671 3Cambrex Reports Second Quarter 2009 Results 53671 4Cambrex Reports Second Quarter 2009 Results 53671 5Cambrex Reports Second Quarter 2009 Results 53671 6Cambrex Reports Second Quarter 2009 Results 53671 7Cambrex Reports Second Quarter 2009 Results 53671 8Cambrex Reports Second Quarter 2009 Results 53671 9Cambrex Reports Second Quarter 2009 Results 53671 10Cambrex Reports Second Quarter 2009 Results 53671 11Cambrex Reports Second Quarter 2009 Results 53671 12